← All trials
NCT04607122
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 28, 2020
- Primary completion
- Dec 7, 2022
- Completion date
- Dec 28, 2022
- First posted
- Oct 29, 2020
- Last posted
- Dec 19, 2020
- Enrollment
- 330
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CHU AMBROISE PARELead sponsor
- CHU AMBROISE PAREStudy chair
- Hôpital Privé Jacques Cartier, Massy, FranceOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.